Project Overview

Led by Dr. Elie Haddad from CHU Sainte-Justine in collaboration with Immugenia, this project includes an inter-provincial research collaboration with Prof. Scott McComb and Prof. Anna Jezierski of the National Research Council of Canada (NRC) and the University of Ottawa who are advancing research innovations through the NRC’s Disruptive Technology Solutions for Cell & Gene Therapy Challenge program. Awarded through the CQDM-Brain Canada Joint Call for Collaborative Research Projects on the Brain program, the total grant of close to $2.5 million, is notably made possible by $829,262 in funding from the government of Quebec via CQDM, in addition to $1 million in funding from Brain Canada and a commitment of $580,345 from Immugenia. The project will enable Immugenia to accelerate its R&D program and enhance its portfolio of drug candidates while investigating new immunotherapies to treat glioblastoma, a type of cancer that originates in the brain.

Principal Investigator

Elie Haddad , CHU Sainte-Justine

Partners and Donors

CQDM

Immugenia